Publikationen 2011

  • Pharmacogenomics in neurology: current state and future steps. Chan A, Pirmohamed M, Comabella M. Ann Neurol. 2011 Nov;70(5):684-97.

 

  • ABC-Transporters in Inflammatory Brain Disease. Chan A, Gold R, von Ahsen N. Curr Pharm Des. 2011;17(26):2803-7.

 

  • Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Hellwig K, Haghikia A, Gold R. Mult Scler. 17(8):958-63.

 

  • Liposomal Encapsulation of Glucocorticoids Alters Their Mode of Action in the Treatment of Experimental Autoimmune Encephalomyelitis. Schweingruber N, Haine A, Tiede K, Karabinskaya A, van den Brandt J, Wüst S, Metselaar JM, Gold R, Tuckermann JP, Reichardt HM, Lühder F. J Immunol. 187(8):4310-8.

 

  • Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFß1 regulation. Stienen MN, Haghikia A, Dambach H, Thöne J, Wiemann M, Gold R, Chan A, Dermietzel R, Faustmann PM, Hinkerohe D, Prochnow N. Br J Pharmacol. 162(2):491-507.

 

  • Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the NRF2 antioxidant pathway.  Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R. Brain 134(Pt3):678-92.

 

  • Efficacy of fumaric esters in the R6/2 and YAC 128 models of Huntington´s disease. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA. PloS One 31,6(1):e16172.

 

  • Inflammation modulates anxiety in an animal model of multiple sclerosis. Peruga I, Hartwig S, Thöne J, Hovermann B, Gold R, Juckel G, Linker RA. Behav Brain Res. 220(1):20-9.

 

  • Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Thöne J, Gold R. Expert Opin Drug Metab Toxicol. 7(3):365-70.

 

  • PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.Taherzadeh-Fard E, Saft C, Akkad DA, Wieczorek S, Haghikia A, Chan A, Epplen JT, Arning L. Mol Neurodegener. 6:32.

 

  • Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Baraniskin A, Kuhnehenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. Blood. 117(11):314-6.

 

  • Functional Energetics of CD4-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders. Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Lindå H, Ziemssen T, Baranzini SE, Käll TB, Bengel D, Olsson T, Gold R, Chan A. PLoS One. 6(4):e18506.

 

  • Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.  Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J. Lancet Neurol. 10:745-58.

 

 
 
  • Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Tumani H, Deisenhammer F, Giovannoni G, Gold R, Hartung HP, Hemmer B, Hohlfeld R, Otto M, Stangel M, Wildemann B, Zettl UK. Ann Neurol. 2011 Sep;70:520

 

  • Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. Gold R. CNS Drugs. 2011 Jan 1;25(1):37-52.
 

Modulation of autoimmune demyelination by laquinimod via induction of brain derived neurotrophic factor